Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
YagamiNGO:7488 +1.31%69 Debt-to-Equity is 0.02 as of Apr. 2026, which is at its 10-year median of 0.02. GuruFocus rates NGO:7488 with a GF Score™ of 69/100 and a GF Value™ of 円3,137.65 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 99 Medical Distribution companies, Yagami ranks better than 96.97% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Yagami's Debt-to-Equity or its related term are showing as below:
NGO:7488'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.02 Max: 0.03
Current: 0.02
During the past 13 years, the highest Debt-to-Equity Ratio of Yagami was 0.03. The lowest was 0.01. And the median was 0.02.
NGO:7488's Debt-to-Equity is ranked better than 96.97% of 99
companies
in the Medical Distribution industry
Industry Median: 0.48
vs NGO:7488: 0.02
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Yagami Debt-to-Equity Related Terms
Yagami Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Yagami's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGO:7488 vs MCK, COR, CAH: Debt-to-Equity Comparison
For the Medical Distribution subindustry, Yagami's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yagami Debt-to-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Yagami's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Yagami's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yagami (NGO:7488) has a Debt-to-Equity of 0.02 as of Apr. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Yagami and its competitors. This is near median its historical median of 0.02. Over the past decade, Yagami's Debt-to-Equity has ranged from 0.01 to 0.03. According to the industry distribution chart, Yagami ranks #3 out of 99 companies in the Medical Distribution industry, placing it in the top 3%.
Is Yagami's Debt-to-Equity too high?
Yagami's current Debt-to-Equity of 0.02 is near median its 10-year median of 0.02. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.03. The Medical Distribution industry median Debt-to-Equity is 0.48. Yagami's value of 0.02 is 95.8% below this industry median. Based on the distribution chart, Yagami ranks #3 out of 99 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Yagami has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Yagami's Debt-to-Equity compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Yagami ranks #3 out of 99 companies for Debt-to-Equity. This places Yagami in the top 3% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.48. Yagami's value of 0.02 is 95.8% below this benchmark. Historically, Yagami's own Debt-to-Equity has ranged from 0.01 to 0.03 over the past decade. While the company's 10-year median is 0.02 vs. the industry median of 0.48, Yagami has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Distribution company?
The median Debt-to-Equity among Medical Distribution companies is 0.48, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Yagami's current Debt-to-Equity of 0.02 is 95.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Yagami and its competitors. For the Medical Distribution industry, the median Debt-to-Equity is 0.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yagami's current Debt-to-Equity is 0.02, which is near median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yagami stock overvalued right now?
Based on GuruFocus' analysis, Yagami (NGO:7488) is currently considered Significantly Overvalued. The stock's GF Value™ is 円3,137.65, compared to a current price of 円5,030.00 — trading 60.3% above its estimated fair value. The current Debt-to-Equity is 0.02, which is near median its 10-year median of 0.02 and 95.8% below the Medical Distribution industry median of 0.48. Yagami's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Yagami (NGO:7488), the current Debt-to-Equity is 0.02 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Yagami (NGO:7488) Overvalued in 2026?
Based on GuruFocus' analysis, Yagami stock appears to be overvalued.
The current stock price of 円5,030.00 is trading 60.3% above its estimated GF Value™ of 円3,137.65.
GuruFocus considers Yagami to be Significantly Overvalued.
Key valuation signals for NGO:7488:
Debt-to-Equity: 0.02 (near median its 10-year median of 0.02)
GF Value™: 円3,137.65 vs. price of 円5,030.00 (60.3% above fair value)
Industry Position: 95.8% below the Medical Distribution median (#3 of 99)
No single metric tells the full story. See the NGO:7488 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Yagami Inc is a Japan based company engaged in providing science education equipment, laboratory tables, kitchen tables, sterilizers, nurse's office equipment, AEDs (automated external defibrillators), human body models for resuscitation education, electric heaters for keeping warm and heating, and environmental testing equipment.
69GF Score
Get the complete analysis for NGO:7488
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGO:7488 has been successfully added to your 
